Principles of Surgical Management of Peritoneal Mesothelioma.
Jessica A Steadman, Travis E Grotz
https://pubmed.ncbi.nlm.nih.gov/37673112/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-10-26
66
Participants Needed
41
Research Sites
N/A
Total Duration
Researchers are investigating treatments for peritoneal mesothelioma, a rare cancer affecting the lining of the abdomen. This phase II trial compares the usual combination of carboplatin, pemetrexed, and bevacizumab chemotherapy with or without the addition of atezolizumab immunotherapy. The study aims to see if adding atezolizumab improves tumor response rates and patient outcomes. Participants are randomly assigned to one of two groups. One group receives intravenous atezolizumab along with carboplatin, pemetrexed, and bevacizumab every 21 days for up to four cycles, followed by surgery and heated chemotherapy inside the abdomen HIPEC. Those unable to undergo surgery may continue maintenance treatment with atezolizumab and bevacizumab. The other group receives carboplatin, pemetrexed, and bevacizumab, also followed by surgery and HIPEC, with optional maintenance therapy at the investigators discretion. Throughout the study, patients undergo CT and PET scans and provide blood and tissue samples. Participants are closely monitored with scans and lab tests to assess tumor response, safety, and surgical outcomes. Follow-up visits occur every six months for up to three years after treatment to track progression-free and overall survival. The study also explores blood biomarkers that might predict clinical outcomes. This thorough evaluation helps researchers understand the benefits and risks of adding immunotherapy to standard chemotherapy for peritoneal mesothelioma.
CONDITIONS
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Chemotherapy + Bevacizumab + Atezolizumab | Chemotherapy + Bevacizumab |
|---|---|---|
| What it is | A combination of carboplatin, pemetrexed, bevacizumab, and the PD‑L1 inhibitor atezolizumab, given after cytoreductive surgery and HIPEC in patients with peritoneal mesothelioma. | The same chemotherapy backbone—carboplatin, pemetrexed, and bevacizumab—without the immunotherapy component. |
| Role in trial | Investigational treatment arm | Active comparator arm reflecting current chemotherapy backbone |
| Primary use | To evaluate whether adding atezolizumab to chemotherapy improves response rate and survival outcomes. | To measure outcomes using a chemotherapy‑based regimen that serves as the current backbone treatment. |
| How it is given or performed | Intravenous carboplatin, pemetrexed, and bevacizumab plus IV atezolizumab after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). | Intravenous carboplatin, pemetrexed, and bevacizumab administered following cytoreductive surgery and HIPEC. |
| Evidence status | Efficacy is under investigation in this randomized trial; no results available yet. | Efficacy is based on chemotherapy regimens used in mesothelioma, but evidence in peritoneal subtype remains limited. |
| Important limitations | Unknown whether the addition of immunotherapy provides meaningful benefit in a rare disease population; sample size may limit generalizability. | Lack of well‑established efficacy data for this chemotherapy combination specifically in peritoneal mesothelioma. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Initial assessments including scans and lab tests
Duration - Approximately 4 to 6 months including chemotherapy, surgery, and maintenance
Participants receive either chemotherapy with carboplatin, pemetrexed, and bevacizumab alone or combined with atezolizumab. Treatment cycles are given every 21 days for up to 4 cycles. After chemotherapy, participants undergo cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Those ineligible for surgery may receive maintenance therapy.
Treatment visits every 21 days; surgery visit; maintenance visits every 21 days if applicable
Duration - Up to 3 years
After completing treatment, participants are monitored with scans, blood tests, and clinical evaluations every 6 months for up to 3 years to assess disease status and overall health.
Visits every 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jessica A Steadman, Travis E Grotz
https://pubmed.ncbi.nlm.nih.gov/37673112/National Cancer Institute (NCI)
Lead Sponsor